Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Фаза 2
Прекращено
NCT06585150
| Заболевание | RSV Infection |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Gilead Sciences |
|---|
| Статус | Прекращено |
|---|
| Участники | 150 участн. |
|---|
| Вмешательство | Obeldesivir, Obeldesivir Placebo |
|---|
| Дата начала | 14.10.2024 |
|---|
| Дата завершения | 8.05.2025 |
|---|
| Публикация результатов | 30.06.2026 |
|---|
Кратко
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
Up to Day 15 · days
| Obeldesivir | 3.2 days |
|---|
| Placebo | 3.9 days |
|---|
| p-value | 0.2005 |
|---|
| Difference in median time | -0.7 |
|---|
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 13.5 percentage of participants |
|---|
| Placebo | 16.2 percentage of participants |
|---|
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 59.5 percentage of participants |
|---|
| Placebo | 57.5 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.